Main content

    Colorectal Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer
    Description: This study is to examine if Nivolumab alone or in combination with Ipilimumab will demonstrate a meaningful objective response rate in patients with recurrent and metastatic colon cancer who also have a specific biomarker in their tumors
    Investigators: Ari Baron, MD
    Eligibility: Male & female subjects, 18 y/o and older, with histologically confirmed colorectal cancer
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study BMS CA209-142

    Title: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
    Description: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects with colon cancer without rectal cancer
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study CALGB 80702

    Title: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac-PACES
    Description: The study is to evaluate the effectiveness of the combination of eflornithine and sulindac in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer
    Investigators: NCI - National Cancer Institute
    Eligibility: Male & female subjects, 18 y/o and older, with a history of Stage 0-III colon cancer with primary resection 1 year previously. Patients with rectosigmoid cancers are eligible if no RT administered
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study SWOG S0820

    Title: Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
    Description: This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be removed by surgery
    Investigators: NCI - National Cancer Institute
    Eligibility: Male & female subjects, 18 y/o and older, with a histologically or cytologically documented adenocarcinoma of the colon or rectum that is either metastatic, or locally advanced and unresectable
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study SWOG S1406

    Title: A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
    Description: The purpose of this study is to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer
    Investigators: Ari Baron, MD
    Eligibility: Subjects, 18 years and older, with a histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic
    Status: Coming soon
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Incyte 267

    Title: An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy
    Description: The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated
    Investigators: Ari Baron, MD
    Eligibility: Subjects, 18 years and older, who have adenocarcinoma of the colon or rectum and who have failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Taiho E.A.P.

    Title: A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision
    Description: The purpose of this study is to compare the effects of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects, 18 years and older, who have a diagnosis of rectal adenocarcinoma and radiologically measurable or clinically evaluable disease as defined in the protocol
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study NCCTG N1048

    • updated July 2015

    Back to top